SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 144 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2015. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $290,000 | -6.1% | 50,177 | -1.9% | 0.00% | 0.0% |
| Q1 2016 | $309,000 | -33.7% | 51,127 | 0.0% | 0.00% | -33.3% |
| Q4 2015 | $466,000 | +27.3% | 51,127 | -21.3% | 0.00% | 0.0% |
| Q3 2015 | $366,000 | +14.0% | 64,986 | +124.2% | 0.00% | +50.0% |
| Q2 2015 | $321,000 | -43.0% | 28,986 | -19.5% | 0.00% | -50.0% |
| Q1 2015 | $563,000 | +3.1% | 35,986 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $546,000 | +49.6% | 35,986 | +5.9% | 0.00% | +33.3% |
| Q3 2014 | $365,000 | -31.5% | 33,986 | -2.9% | 0.00% | -40.0% |
| Q2 2014 | $533,000 | -15.7% | 34,986 | 0.0% | 0.01% | -16.7% |
| Q1 2014 | $632,000 | +25.9% | 34,986 | -3.3% | 0.01% | +20.0% |
| Q4 2013 | $502,000 | +29.7% | 36,186 | -2.2% | 0.01% | 0.0% |
| Q3 2013 | $387,000 | +34.4% | 36,986 | 0.0% | 0.01% | +25.0% |
| Q2 2013 | $288,000 | +274.0% | 36,986 | +182.9% | 0.00% | -63.6% |
| Q2 2011 | $77,000 | – | 13,076 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |